Sophie E. Willis

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity

Jacqueline H. L. Fok, Antonio Ramos‐Montoya, Mercedes Vázquez–Chantada et al. · Nature Communications · 2019 · 334 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer

Seung Tae Kim, Simon A. Smith, Peter G. Mortimer et al. · Clinical Cancer Research · 2021 · 79 citations · Full text

Medicine, Oncology, Pharmacology +15

Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response

Sophie E. Willis, C Winkler, Martine P. Roudier et al. · British Journal of Cancer · 2021 · 51 citations · Full text

Medicine, Oncology, Pharmacology +14

Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation

Magnus T. Dillon, Jeane Guevara, Kabir Mohammed et al. · Journal of Clinical Investigation · 2023 · 48 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in <i>KRAS</i> -Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib

Vikki Flemington, Emma Jane Davies, David M. Robinson et al. · Molecular Cancer Therapeutics · 2020 · 26 citations

Medicine, Oncology, Pharmacology +17